PERSONAL:
Born: February 25, 1944, St. Petersburg,
Florida.
Citizenship: USA.
ADDRESSES:
Business: Keck
Graduate Institute
535 Watson Drive
Claremont, California 91711
Phone: 909 607-7855
Home: 854
Guanajuato Drive
Claremont, California 91711
Phone: 909 398-1330
EDUCATION:
1972 University
of California, Davis-Livermore, Physics Ph.D.
Dissertation: “Theory of Interaction of Impurities with
Liquid Helium”
1968 University
of California, Davis-Livermore, Physics M.S.
1967 University
of California, Berkeley, Physics
A.B. with honors
Other:
Cold Spring Harbor Laboratory
Summer
study in the Molecular Biology & Genetics of Yeast 1974
Cold Spring Harbor Laboratory
Summer study in Advanced Molecular
Genetics of Bacteria 1975
PROFESSIONAL
POSITIONS:
2002 – present Chancellor,
Chief Scientific Officer and Norris Professor of Applied Life
Sciences
Keck Graduate Institute of Applied Life Sciences
1998 – 2002 Chief Academic
Officer, Dean of Faculty, Vice President, Norris Professor of Applied Life Sciences
Keck Graduate Institute of Applied
Life Sciences
2002 – present Adjunct Professor, Department of Bioengineering, University of California,
San Diego
1998- 2000 Chief Science
Advisor
Chiroscience R&D Inc. &
Rapigene Inc.
1997- 1998 President and
Chief Scientific Officer, Director
Chiroscience R&D Inc. (formerly
Darwin Molecular Corporation)
1995-1997 Executive Vice President and Chief
Scientific Officer, Director
Darwin Molecular Corporation
1994-1995 President, CEO and Chief Scientific
Officer,
Darwin Molecular Corporation
1993-1994 Vice President for Research and
Development, Founder & Director
Darwin Molecular Corporation
1990-1993 Director for Health and
Environmental Research,
Office of Energy Research, U.S.
Department of Energy
(on leave from University of
Southern California)
1988-1993 Professor of Molecular Biology,
Department of Biological Sciences,
University of Southern California
1985-1990 Director of Molecular Biology
Section,
University of Southern California
1984-1988 Associate Professor, Molecular
Biology Section,
Department of Biological Sciences,
University of Southern California
1981-1984 Assistant Professor, Molecular
Biology Section,
Department of Biological Sciences,
University of Southern California
1977-1981 Charge’ de Recherches, Department of
Molecular Biology,
University of Geneva, Geneva,
Switzerland
1974-1977 Senior Staff Scientist, Biomedical
Division,
University of California,
Lawrence Livermore National
Laboratory, Livermore, California
1972-1974 Scientific Advisor to Defense
Science Board,
Task Force on Strategic
Vulnerability (Capt., USAF)
1967-1972 Hertz Foundation predoctoral fellow
1966-1967 Computational Technician/Programmer,
Theoretical Physics Department, University of California,
Lawrence Livermore National
Laboratory
BOARDS/COMMITTEES:
Board of Directors, Fannie and John Hertz
Foundation, 1999 - present
Board of Directors, Impath Inc., 1999 –
2002 (public corporation, NASDAQ)
Advisory Board, Boston University
Bioinformatics Program, 1999 – present
Selection Committee for the Howard Hughes
Medical Institutes Investigators in Computational
Biology, 1999 – present
Editorial Board, Journal of
Bioinformatics and Computational Biology, 2002 -
Editorial Board, Functional &
Integrative Genomics, 1999 – present
Editorial Board, Journal of Computational
Biology, 1993 - present
Board of Directors, Rapigene Inc., 1998 –
1999 (spin out of Chiroscience plc)
Board of Directors, Chiroscience Group
plc, 1997-1998
(public corporation, London Stock Exchange)
Board of Directors, Blue Heron
Technologies Inc. Seattle WA, 1999-present
Scientific Advisory Board, Blue Heron
Technologies, 2000-present
Scientific Advisory Council, CellTech
Group, 1999 – present
Scientific Advisory Board, Impath Inc.,
1999- present
Policy Board, DOE Joint Genome Institute,
University of California, 2000 – present
Advisory Committee, DOE Joint Genome
Institute, University of California, 1997 – 2000
Laboratory Advisory Committee, Pacific
Northwest National Laboratory, 2001 - present
National Academy of Science, Board on
Biology, 1995- present
National Academy of Science, Commission on
Life Sciences, 1998- 2000
National Biotechnology Policy Board, 1990
- 1993
National Cancer Advisory Board, 1990 –
1993
Board of Governors, National Center for
Genome Resources, Santa Fe, New Mexico, 1995 - present
Scientific Advisory Board, University of
Utah Medical School, Salt Lake City Utah, 1993 - present
Scientific Advisory Board, Valigen Corp.,
Paris, 2000- present
Scientific Advisory Board, Integra
Ventures, 2001 - present
Vice Chairman, Committee on Life Sciences
and Health, Federal Coordinating Committee for
Science Education and Technology (OSTP), 1990 - 1993
Chair, Biotechnology Research
Subcommittee, Committee on Life Sciences and Health,
(OSTP), 1990 – 1993
Chair, Biology Division Advisory
Committee, Los Alamos National Laboratory, 2000- present
Biological System Institute Advisory
Committee, Pacific Northwest National Laboratory, 2001- present
Director’s Advisory Committee, Pacific
Northwest National Laboratory, 2001- present
Committee on Earth and Environmental
Science, Federal Coordinating Committee for Science Education and Technology,
(OSTP), 1991 – 1993
Chairman of the Board, Ionian
Technologies Inc., 2001- present
Chairman
of the Board, Zuyder Pharmaceuticals, Inc., 2001 - present
National Research Council Panel on “The
Scientific and Medical Aspects of Human Cloning,” 2001
National Research Council Steering
Committee Member on “Defining the Mandate of Proteomics in the Post-Genomics
Era,” 2002.
The National Academies, Biological Panel,
Committee on “Science and Technology for Countering Terrorism”, 2002
Scientific Advisory Board of the
Institute for Molecular Bioscience Member, The University of Queensland,
Australia, 2003.
SOCIETIES,
HONORS:
A.B. with Honors in General Scholarship,
UC Berkeley
Rhodes Scholarship finalist, 1966
Fannie and John Hertz Foundation
predoctoral fellowship, 1967-1972
NSF predoctoral fellowship, AEC
predoctoral fellowship, 1967
Friedrich-Miescher Award in Biochemistry,
nominee for DNA "footprinting,”
Swiss Biochemical Society, 1981
Parker Lecture and Award, Batelle-Pacific
Northwest Laboratories
American Physical Society
American Chemical Society
American Society of Human Genetics
American Association for the Advancement
of Science
American Society of Microbiology
Human Genome Organization
Sigma Xi
Genetics Society of America
New York Academy of Science
SUMMARY
OF SCIENTIFIC INTERESTS:
My scientific interests are multiple and
include the application of a variety of disciplines to solving biological and
medical problems. This includes
mathematical and computational methods, as well as the use of physical methods
and synthetic chemistry in the development of novel approaches to the analysis
of biological systems at the molecular level.
These particular interests are evident in my role in founding and
managing a new biotechnology company, Darwin Molecular Corporation (DMC), which
has now become a part of Celltech plc through Chiroscience Group plc via a
series of acquisitions. DMC was founded
in 1993 to take advantage of new developments in gene discovery and
combinatorial chemistry to forge a gene-to-drug discovery capability within a
small company. These ambitions are
still being realized, but the work-in-progress has included the discovery of
the Werner’s Syndrome gene (the first human gene found to directly affect
aging), and a gene for susceptibility to early onset Alzheimer’s disease, a
novel human gene involved in the control of bone density, and the development
of several novel technologies for rapid genotyping, gene expression profiling,
and several other genomic analysis methods.
The later resulted in the founding of a new company in 1998, Rapigene
Inc. Most recently we have founded an
enabling technology company, Ionian Technologies Inc., based on advances
achieved in my laboratory at the Keck Graduate Institute. The various technological advances in
methods for the amplification and measurement of nucleic acids has the
potential to contribute significantly to bringing the benefits of the life
sciences to society.
Policy interests that I have pursued in
my governmental work include the nature of the effects of technological
developments on the advance of biological research and applications in public
and private sectors, and the interactions of these sectors. My involvement in the leadership of the
Human Genome Program (the DOE component of the project was my responsibility
from 1990 to 1993) has sharpened those interests and convinced me of the major
role to be played by technology in the future of all the basic and applied life
sciences. Both anticipation of
scientific advances and the formulation of effective policy for research are
strongly affected by this connection.
My involvement in directing and coordinating the FY 1993, multi-agency,
Presidential Initiative in Biotechnology Research (see the 1993 Presidential
Report Entitled, "Biotechnology For the 21st Century" and the
follow-on document for 1994) has given me a deeper appreciation of the
fundamental nature of basic-applied-technology feedback loops that operate over
a wide range of modern scientific research activities. Other policy-related research interests
include radiation effects, mutagenesis and carcinogenesis, and in particular
the effects of specific genotypes on the biological manifestation of DNA
damage, and other pathogenic processes.
A principal laboratory research interest
of mine pursued over the past fifteen years or so, has been in understanding
the mechanisms of transposition of transposable genetic elements, and the
biological significance of their activities in living cells. Another long-standing area of interest
involves the study of DNA-protein interactions in a larger sense than those
aspects that have been connected with the transposition work.
Recent interests have included nucleic
acid analysis technologies for genetics and functional genomics, and the study
of biological networks.
GOVERNMENT
AND INDUSTRY EXPERIENCE:
My experience in government service as
Director of Health and Environmental Research in the Department of Energy from
1990 to 1993 was in running the programs of research in biological and
environmental science funded by the Department of Energy. This research was carried out in the
National laboratories and Universities across the country, and covered a wide
range of areas in basic and applied science and technology, including most
notably the component of the Human Genome Project of the Department of
Energy. The DOE component was
approximately one half the size of the NIH program. The government rank of my position was at the equivalent of a
Deputy Assistant Secretary. The
research budget managed in 1993 was approximately $430M. My objectives in this job were to maximize
the effectiveness and scientific strength of the Human Genome Program,
re-invigorate the DOE programs with research that takes full advantage of the
many new molecular and computational technologies, and to integrate and realign
existing programs with these goals. I
was substantially successful in setting these programs on the path to meeting
these objectives (see paper on the five year plan for the Human Genome Project
in Science, 1993).
In the private sector I was one of six
founders of Darwin Molecular Corporation, a biotechnology company focused on an
integrated technological approach to drug discovery that began with gene
discovery and used combinatorial chemistry methods to developed drug leads
against newly defined targets. This
plan for a small company was considered heretical at the time, but has since
become commonplace in the industry. I
was the chief scientific officer from the company’s inception and have also
held other positions as needed, including CEO, and most recently President of
the US component of the larger merged company.
We were successful in discovering several significant new genes
including the gene for Werner’s syndrome, the first human gene known to directly
affect aging, and an Alzheimer’s disease susceptibility gene, PS2, a new human
bone density gene, and several others that are now making contributions to the
current company pipeline, and have a good chance of contributing to the
effective treatment of osteoporosis.
The company merged in January 1997 with an UK company, Chiroscience plc,
which was focused on chemistry, and pre-clinical and clinical drug
development. I remained the President
and Chief Scientific Officer of the US part of the combined company until my
resignation in 1998 to assume my present position at KGI. With some new technology developed in Darwin
Molecular at the foundation, we formed a new subsidiary, Rapigene, in March
1998 to develop and commercialize this genotyping and gene expression
measurement technology. Chiroscience
plc was acquired by Celltech plc in 1999.
In September 1998 I relinquished all management responsibilities for Chiroscience and assumed a part time advisory role in order to assume the post of Chief Academic Officer of a new academic venture, the Keck Graduate Institute of Applied Life Sciences. KGI was formed to develop an entirely new type of graduate training and research program focused primarily on training professionals in the applied life sciences. Integrating a range of technical and management components, KGI will train leaders for the future of the biotechnology, health care and pharmaceutical industry, and carry out focused research on a variety of applied problems in the life sciences. One designated area of focus will be on the applications of computational and theoretical methods to applied problems in the life sciences. The institute is the newest chartered member of the Claremont College consortium and has the potential to contribute to significant change in training in the life sciences, particularly for applications.
PUBLICATIONS:
Galas, D. J., “Galilean Covariance of Gauge Fields and the Quantization of
Circulation in He II,” Lettre Al
Nuovo Cimento 2:217 (1971).
Galas, D. J., “Theory of the Interaction of Impurities with Superfluid
Helium,” PhD Dissertation submitted to
the University of California (1972).
Galas, D. J., Jensen, C. A. and Sahlin,
H. L., “A Computable Expansion for
Multiparticle Propagators,” Journ.
Mathematical Physics 14:524 (1973).
Galas, D. J., “The Superleak as a Gyroscope,” Journ. of Applied Physics
44:2355 (1973).
Branscomb, E. W. and Galas, D. J., “Progressive Decrease in Protein Synthesis
Accuracy Induced by Streptomycin in E.
coli,” Nature 254:161-163 (1975).
(reprinted in Benchmark Papers in Genetics Series, Genes,
Proteins and Cellular Aging, ed. R. Holliday, van Nostrand Reinhold Co.,
New York, (1976).
Galas, D. J. and Branscomb, E. W., “Ribosome Slowed by Mutation to Streptomycin
Resistance,” Nature 262:617-619
(1976).
Galas, D. J. and Branscomb, E. W., “The Enzymatic Determinants of DNA
Polymerase Accuracy: Theory of T4 Polymerase Mechanisms,” J. Mol. Biol. 124:653-687 (1978).
Calos, M. P., Galas, D. J. and Miller, J.
H., “Genetic Studies of the lac Repressor, VIII. DNA Sequence Change Resulting from an
Intragenic Duplication,” J. Mol.
Biol. 126:865-869 (1978).
Galas, D. J., “An Analysis of Sequence Repeats in the lacI Gene of E. coli,” J. Mol. Biol. 126:858-863 (1978).
Galas, D. J., “On the Symmetries of Multipalindromic DNA Sequences,” J.
Theor. Biol. 72:57-73 (1978).
Galas, D. J. and Schmitz, A., “DNAase Footprinting: A Simple Method for
the Detection of Protein-DNA Binding Specificity,” Nucleic Acids Res. 5:3157-3170 (1978).
Miller, J. H., Coulondre, C., Schmeissner,
U., Schmitz, A. and Galas, D. J.,
“Altered lac Repressors
Generated by the Supression of Nonsense Mutations, in Nonsense Mutations and
tRNA Suppressors,” (eds. J. E., Celis and J. D. Smith) Academic Press,
London (1979).
Clayton, L. K., Goodman, M. F.,
Branscomb, E. W. and Galas, D. J., “Error Induction and Correction by Mutant
and Wild-Type T4 DNA Polymerases: Kinetic Error Discrimination
Mechanisms,” J. Biol. Chem.
254:1902-1912 (1979).
Schmitz, A. and Galas, D. J., “The Interaction of RNA Polymerase and lac Repressor with the lac Control Region,” Nucleic Acids Res. 6:111-137 (1979).
Schmitz, A. and Galas, D. J., “Sequence-Specific Interaction of the
Tight-Binding 112-X86 lac Repressor
with Non-operator DNA,” Nucleic
Acids Res. 8:487-506 (1980).
Galas, D. J., “Translation and Replication Accuracy: Some Theoretical
Considerations, Proceedings of the
Conference on Structural Pathology of DNA and the Biology of Ageing, Deutsche
Forschungsgemeinschaft, the Zentrallaboratorium für Mutagenitätsprüfung,
Freiburg im Breisgau, BRD,” Harold Boldt Verlag, Bonn, 108 (1980).
Miller, J. H., Calos, M. P., Galas, D.
J., Büchel, D. and Müller-Hill, B.,
“Genetic Analysis of Transposition into the lac Region of E. coli,” J.
Mol. Biol. 144:1-18 (1980).
Galas, D. J., Calos, M. P. and Miller, J.
H., “DNA Sequence Analysis of Tn9 Insertions in the lacZ Gene,” J. Mol.
Biol. 144:19-41 (1980).
Galas, D. J., Miller, J. H., Calos, M.
P., “Genetic and Sequencing Studies of
the Specificity of Transposition into the lac
region of E. coli,” Cold Spring
Harbor Symp. Quant. Biol. 45:243-257 (1981).
Galas, D. J. and Chandler, M., “On the Molecular Mechanisms of
Transposition,” Proc. Nat. Acad.
Sci. 78:4858-4862 (1981).
Chandler, M., Clerget, M. and Galas,
D., “The Transposition Frequency of IS1-flanked Transposons is a Function of
Their Size,” J. Mol. Biol.
154:229-243 (1982).
Galas, D. J. and Chandler, M., “The Structure and Stability of Tn9-Mediated
Cointegrates-Evidence for two Pathways of Transposition,” J. Mol. Biol.
154:245-272 (1982).
Schmitz, A. and Galas, D. J., “The Study of Protein-DNA Binding
Specificity: DNase Footprinting,” (review) in Methods in DNA and RNA
Sequencing, ed. S. Weissmann,76 (1984).
Hirschel, B. H., Galas, D. J. and
Chandler, M., “Cointegrate Formation by
Tn5, but not Transposition, is Dependent on recA,” Proc. Nat. Acad.
Sci. 79:4530-4534 (1982).
Hirschel, B. H., Galas, D. J., Berg, D.
and Chandler, M., “Structure and
Stability of Transposon-5-Mediated Cointegrates,” J. Mol. Biol. 159:557 (1982).
Chandler, M. and Galas, D. J., “IS1-mediated DNA Tandem Duplication
of Plasmid pBR322: Dependence on recA,
and on DNA Polymerase I,” J. Mol.
Biol. 165:183-190 (1983).
Chandler, M. and Galas, D., “Cointegrate Formation Mediated by Tn9.
II. Activity of IS1 is Modulated by DNA Sequences,” J. Mol. Biol., 170:61-91 (1983).
Galas, D. and Smith, T. F., “The Relationship Between Codon Boundaries
and Multiple Reading Frame Preferences: Coding Organization of Bacterial
Insertion Sequences,” Molecular
Biology and Evolution 1:260-268 (1984).
Waterman, M., Arratia, R. and Galas,
D., “Pattern Recognition in Several
Sequences: Consensus and Alignment,” Bull.
Math. Biol. 46:515-527 (1984).
Chandler, M. and Galas, D., “Studies on the Transposition of IS1,” Basic
Life Sci 30:53-77 (1985).
Galas, D., Eggert, M. and Waterman,
M., “Rigorous Pattern Recognition
Methods for DNA Sequences: Analysis of Promoter Sequences for E. coli,” J. Mol. Biol.
186:117-128 (1985).
Galas, D., “An Introduction to the Problem of Accuracy” (review) Chapter in Accuracy
in Molecular Processes: Its Control and Relevance to Living Systems,
Chapman & Hall, London, New York, ed.Kirkwood Rosenberger & Galas
(1986).
Zerbib, D., Gamas, P., Chandler, M.,
Prentki, P., Bass, S. and Galas, D.,
“Specificity of Insertion of IS1,”
J. Mol. Biol. 185:517-524 (1985).
Gamas, P., Galas, D. and Chandler,
M., “DNA Sequence at the End of IS1
Required for Transposition,” Nature
317:458-460 (1985).
Prentki, P., Teter, B., Chandler, M. and
Galas, D., “Functional Promoters
Created by the Insertion of Transposable element IS1,” J. Mol. Biol. 191:383-393 (1986).
Gamas, P., Burger, A.C., Churchward, G.,
Caro, L., Galas, D. and Chandler, M.,
“Replication of pSC101: Effects
of Mutations in the E. coli DNA binding Protein IHF,” Mol. Gen Genet. 204:85-89 (1986).
Prentki, P., Gamas, P., Chandler, M. and
Galas, D., “Functions of the Ends of
IS1,” Replication and Recombination of DNA, Kelly et al.,(eds.)
Alan R. Liss, Inc. pp. 719-734 (1987).
Gamas, P., Chandler, M., Prentki, P. and
Galas, D., “E. coli Integration Host Factor Binds Specifically to the Ends of
the Insertion Sequence IS1 and to its Major Insertion Hot-Spot in pBR322,” J. Mol. Biol. 195:261-272 (1987).
Gamas, P., Caro, L., Galas, D. and
Chandler, M., “Expression of F Transfer
Functions Depends on the E. coli
Integration Host Factor,” Mol. Gen. Genet. 207:302-305 (1987).
Prentki, P., Chandler, M. and Galas,
D., “E. coli Integration Host Factor Bends the DNA at the Ends of IS1
and in an Insertion Hotspot with Multiple IHF Binding Sites,” EMBO Journ. 6:2479-2487 (1987).
Prentki, P., Pham, M. H., Gamas, P.,
Chandler, M. and Galas, D., “Artificial Transposable Elements in the Study of
Insertion Sequence IS1,” Gene
61:91-101 (1987).
Zerbib, D., Jakowec, M. J., Prentki, P.,
Chandler, M. and Galas, D., “Expression of Proteins Essential for IS1
Transposition: Specific Binding of InsA to the Ends of IS1,” EMBO Journ. 6:3163-3169 (1987).
Prentki, P., Pham, M-H. and Galas, D. J., “Plasmid Permutation Vectors to Monitor DNA
Bending,” Nucl. Acids Res.
15:10060 (1987).
Muller, F., Clarkson, S. G. and Galas,
D., “Sequence of a 3.18 kb Tandem
Repeat of Xenopus laevis DNA
containing 8 tRNA Genes,” Nucleic
Acids Res. 15:7191 (1987).
Jakowec, M., Prentki, P., Chandler, M.
and Galas, D., “Mutational Analysis of
the Open Reading frames of IS1: Proteins Required for Transposition,” Genetics 120:47-55 (1988).
Galas, D. and Chandler, M., “Bacterial Insertion Sequences” (review) chapter
4 in Mobile DNA, pp. 109-162, American Society for Microbiology,
Washington, D.C. (1989).
Hemsley, A., Arnheim, N. and Galas, D.
J., “A Simple Method for Site-directed
Mutagenesis Using the Polymerase Chain Reaction,” Nucleic Acids Res. 17:6545-6551 (1989).
Zerbib, D., Chandler, M., Freund, E.,
Prentki, P. and Galas, D., “Functional Organization of the Ends of IS1:
Specific Binding Site for an IS1-encoded Protein,” The EMBO Journal,
9:456-463 (1990).
Cui, X., Li, H., Goradia, T. M., Lange,
K., Kazazian, H. H., Galas, D. J. and Arnheim, N., “Single Sperm Typing: Determination of Genetic Distance Between
the G globin and Parathyroid hormone Loci,” Proc. Natl. Acad. Sci., USA
86:9389-9393 (1989).
Galas, D., “Transposable Genetic Elements: Agents of Complex Change,” Prog.
Clin. Biol. Res., 340A: 135-144
(1990).
Branscomb, E. W., Slezak, T., Galas, D.
J., Pae, R., Carrano, A. V. and Waterman, M. S., “Optimizing Restriction Fragment Fingerprinting Methods for
Ordering Large Genomic Libraries,” Genomics 8:351-366 (1990).
Zerbib, D., Prentki, P., Gamas, P.,
Freund, E., Galas, D.J., and Chandler, M., “Functional Organization of the Ends
of IS1: Specific Binding Site for an
IS1-encoded Protein,” Molecular Microbiology, 4(9):1477-1486 (1990).
Zerbib, P., Polard, P., Escoubas, J. M.,
Galas, D.J., and Chandler, M., “The Regulatory Role of the IS1-encoded InsA
Protein in Transposition,” Molecular Microbiology, 4(3):471-477 (1990).
Zerbib, D., Polard, P., Escoubas, J. M.,
Chandler, M. and Galas, D., “The Regulatory Role of the IS1-encoded InsA
Protein in Transposition,” Mol. Microbiol. 5(2):1477-1486 (1991)
Escoubas, J.M., Prere, M.F., Fayet, O.,
Salvignol, I., Galas, D. J., Zerbib, D., and Chandler, M., “Translational
Control of Transposition Activity of the Bacterial Insertion Sequence IS1,” The
EMBO Journal, 10:705-712, (1991).
Collins, F., Galas, D. J., “A New
Five-year Plan for the U. S. Human Genome Project,” Science, 262: 43-46
(1993).
Galas, D. J., “Important Unanswered
Questions Concerning Radiation Risk Estimates,” Radiat. Res.,
136:139-143, (1993).
Betermier, M., Galas, D. J., “Interaction
of Fis Protein with DNA: Bending and Specificity of Binding,” Biochimie.,
76:958-967, (1994).
Levy-Lahad E., Wasco W., Poorkaj P.,
Ramano D., Oshima J., Pettingell W., Yu C., Jondro P., Schmidt S., Wang K.,
Crowley A., Fu YH., Guenette S., Galas D., Nemens E., Wijsman E., Bird T.,
Schellenberg G., Tanzi R., “Candidate Gene for the Chromosone 1 Familial
Alzheimer’s Disease Locus,” Science 269:973-977 (1995).
Sun F, Galas, D. J., and Waterman, M.S.,
“A Mathematical Analysis of In Vitro Molecular Selection-Amplification,” J
Mol. Biol., 258:650-660, (1996).
Galas, D. J., “Novel Genes Novel
Functions and New Drugs,” Pharmaceutical Forum, 8:22-25 (1997).
Galas, D. J., “New Genetic Tools: Their
Roles in Drug Discovery and Development,” International Journal of
Pharmaceutical Medicine, 12:13-18 (1998).
Teter, B., Goodman, S. D., and Galas, D.
J., “DNA Bending and Twisting Properties of Integration Host Factor Determined
by DNA Cyclization,” Plasmid 43:73-84 (2000)
Brunkow, M., Jeffery, E., Hjerrild, K.,
Paeper, B., Clark, L., Wilkinson, J.E., Galas, D., Ziegler, S., Ramsdell,
F., “Disruption of a New
Forkhead/Winged-Helix Protein, Scurfin, Results in the Rapidly Fatal
Lymphoproliferative Disorder of the Scurfy (sf) Mutant Mouse,” Nature
Genetics, 27:68-73, (2001).
Brunkow, M., Gardner, J., Van Ness, J.,
Paeper, B., Kovacevich, B., Proll, S., Skonier, J., Zhao,
L., Sabo, P.J., Fu, Y., Alisch, R., Gillett,
L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H.,
Beighton, P., Mulligan, J., “Bone
Dysplasia Sclerosteosis Results from Loss of the SOST Gene
Product, a Novel Cystine Knot-Containing
Protein,” American Journal of Human Genetics,
68:577-589, (2001).
Strahling-Hampton, K. Proll, S., Paeper, B., Zhao, Lei, Charmley, P., Brown, A., Gardner, J., Galas, D.J., Schatzman, R., Beighton, P., Papapoulos, S., Hamersma, H., and Brunkow, M, “ A 52kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem’s disease in the Dutch population,” American Journal of Medical Genetics, Jun 15: 110 (2): 144-152, (2002).
Dewey,
T.G., Galas, D., “Dynamic Models of Gene Expression and Classification,” Functional
and Integrative Genomics, 1:269-278, (2001).
Galas,
D., Dewey, T.G., “Integration of New
Technologies in the Future of the Biological Sciences, Firepower in the
Lab: Advanced Automation in the Fight
Against Biological Threat,” (eds.
Layne and Beugelsdijk) Joseph Henry Press, Washington, D.C., pp.
227-242 (2001).
Galas, D.J., “Making Sense of the
Sequence,” Science, 291:1257-60, (2001).
Galas, D.J., “The Invention of
Footprinting”, Trends in Biochemical Sciences, 26:690-693, (2001).
Galas, D.J., “Against giants or windmills? The struggle for the human genome.” Trends
in Biochemical Sciences, 27:324-325, (2002).
National Research Council Steering Committee: George L. Kenyon, David M. DeMarini, Elaine
Fuchs, David J. Galas, Jack F. Kirsch, Thomas S. Leyh (contributing author),
Walter H. Moos, Gregory A. Petsko, Dagmar Ringe, Gerald M. Rubin, and Laura C.
Sheahan (Staff Director), “Defining the Mandate of Proteomics in the
Post-Genomic Era: Workshop Report,” Molecular
& Cellular Proteomics, 1:763-780, (2002).
Hood, L. and Galas, D.J., “The Digital
Code of DNA,” Nature, 421:444-448, (2003)
Bhan, A., Galas, D. J. and Dewey, T.G.,
“A Duplication Growth Model of Gene Expression Networks,” Bioinformatics, 18,
1486-1493 (2002)
Chung, F., Dewey, T.G., Lu Liang, and
Galas, D. J. “Duplication Models and Biological Networks,” Journal of
Computational Biology (in press,
2003).
Van Ness, J., Van Ness, L., Galas, D.J.,
“Isothermal Reactions for the Amplification of Oligonucleotides,” PNAS,
April 15, 100: 4504-4509 (2003).
Van Ness, J., Erwin, B., Galas, D.J.,
“Self-Amplifying Arrays,” Science, (Submitted, 2003)
Galas, David J., Riggs, Henry, “Global
Science and U.S. Security,) Science, 300: 1847, (2003).
BOOKS:
Kirkwood, T. B. L., Rosenberger, R. and
Galas, D. (editors), Accuracy in
Molecular Processes: Its Control and Relevance to Living Systems, Chapman and Hall, London and New York, 398
pages (1986).
Galas, D., and McCormack, S.,